Carisma Therapeutics (CARM) said Sunday that new preclinical data showed the potential of the company's engineered macrophages in multiple liver fibrosis models.

Results of the study showed that the engineered macrophages significantly reduced liver fibrosis and hepatic stellate cell activation. The engineered macrophages were also well tolerated in the study, the company said.

The company anticipates to nominate a development candidate for its liver fibrosis program in Q1 2025.

Price: 1.0407, Change: -0.01, Percent Change: -0.89